Overview on fosfomycin and its current and future clinical significance

1. Allerberger F., Klare I.: In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J. Antimicrob. Chemother., 43, 211, 1999.Search in Google Scholar

2. Bader M.S., Hawboldt J., Brooks A.: Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad. Med., 122, 7, 2010.Search in Google Scholar

3. Baltz R.H., Daptomycin: mechanisms of action and resistance and biosynthetic engineering. Curr. Opin. Chem. Biol., 13, 144, 2009.Search in Google Scholar

4. Baylan O.: Fosfomycin: past, present and future. Mikrobiyol. Bul., 44, 311, 2010.Search in Google Scholar

5. Bayrak O. et al.: Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy? Int. Urogynecol. J., 18, 525, 2007.10.1007/s00192-006-0190-ySearch in Google Scholar

6. Bocher H.W. et. al.: Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis., 48, 1, 2009.Search in Google Scholar

7. Cassir N., Rolain J.M., Brouqui P.: A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front. Microbiol., 5, 1, 2014.Search in Google Scholar

8. Chareancholvanich K., Udomkiat P., Waikakul S.: A randomized control trial between fosfomycin and cefuroxime as the antibiotic prophylaxix in knee arthroplasty. J. Med. Assoc. Thai., 9, 6, 2012.Search in Google Scholar

9. Chen L.Y. et al.: High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report. BMC. Infect. Dis., 11, 1, 2011.10.1186/1471-2334-11-152Search in Google Scholar

10. Eschenburg S., Priestman M., Schonbrunn E.: Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J. Biol. Chem., 280, 3757, 2005.Search in Google Scholar

11. Falagas M.E. et al.: Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimentaland clinical evidence. J. Antimicrob. Chemother., 60, 7, 2007.10.1093/jac/dkm137Search in Google Scholar

12. Falagas M.E. et al.: Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis., 46, 1069, 2008.10.1086/527442Search in Google Scholar

13. Falagas M.E. et al.: Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents., 34, 111, 2009.10.1016/j.ijantimicag.2009.03.009Search in Google Scholar

14. Falagas M.E.et al.: Fosfomycin for the treatment of multidrugresistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet. Infect. Dis., 10, 43, 2010.10.1016/S1473-3099(09)70325-1Search in Google Scholar

15. Falagas M.E. et al.: Antimicrobial susceptibility of multidrugresistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents., 35, 240, 2010.10.1016/j.ijantimicag.2009.10.01920034765Search in Google Scholar

16. Gardiner B.J., et al.: Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin. Infect. Dis., 58, 101, 2014.Search in Google Scholar

17. Giamarellou H.: Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents., 36, 50, 2010.10.1016/j.ijantimicag.2010.11.01421129924Search in Google Scholar

18. Hamilton-Miller J.M.: In vitro activity of fosfomycin against “problem” Gram-positive cocci. Microbios., 1992, 71: 95-103.Search in Google Scholar

19. Hauser C. et al.: In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob. Agents. Chemother., 59, 1605, 2015.10.1128/AAC.04536-14432578325547354Search in Google Scholar

20. Kaase M. et al.: Fosfomycin in susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J. Clin. Microbiol. 52, 1893, 2014.10.1128/JCM.03484-13404275324648559Search in Google Scholar

21. Kahan FM. et al.: The mechanism of action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci., 235, 364, 1974.10.1111/j.1749-6632.1974.tb43277.x4605290Search in Google Scholar

22. Karageorgopoulos D.E. et al.: Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J. Antimicrob. Chemother., 67, 255, 2012.10.1093/jac/dkr46622096042Search in Google Scholar

23. Keating G.M.: Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs., 73, 1951, 2013.10.1007/s40265-013-0143-y24202878Search in Google Scholar

24. Ko K.S. et al.: In vitro activity of fosfomycin against ciprofloxacinresistant or extended-spectrum β-lactamase-producing Escherichia coli isolated from urine and blood. Diagn. Microbiol. Infect. Dis., 58, 111, 2007.10.1016/j.diagmicrobio.2006.11.01517300900Search in Google Scholar

25. Lepe J.A. et al.: In vitro and intracellular activities of fosfomycin against clinical strains of Listeria monocytogenes. Int. J. Antimicrob. Agents., 43, 135, 2014.10.1016/j.ijantimicag.2013.10.01824315790Search in Google Scholar

26. Livermore D.M. et al.: What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocyllin and tigecycline. Int. J. Antimicrob. Agents., 37, 415, 2011.10.1016/j.ijantimicag.2011.01.01221429716Search in Google Scholar

27. Lu C.L. et al.: Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob. Agents Chemother., 55, 4295, 2011.10.1128/AAC.00349-11316535221670185Search in Google Scholar

28. Mazzei T. et al.: Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. J. Antimicrob. Agents., 28, 35, 2006.10.1016/j.ijantimicag.2006.05.01916829051Search in Google Scholar

29. Michalopoulos A.S., Livaditis I.G., Gougoutas V.: The revival of fosfomycin. Int. J. Infect. Dis., 15, 732, 2011.Search in Google Scholar

30. Michalopoulos A. et al.: Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect., 16, 184, 2010.10.1111/j.1469-0691.2009.02921.x19694767Search in Google Scholar

31. Pontikis K. et al.: Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrugresistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int. J. Antimicrob. Agents., 43, 52, 2014. 10.1016/j.ijantimicag.2013.09.01024183799Search in Google Scholar

32. Poulakou G. et al.: Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future. Microbiol., 9, 1053, 2014.10.2217/fmb.14.5825340835Search in Google Scholar

33. Raz R.: Fosfomycin: an old-new antibiotic. Clin. Microbiol. Infect., 18, 4, 2012.10.1111/j.1469-0691.2011.03636.x21914036Search in Google Scholar

34. Reffert J.L., Smith W.J.: Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the society of infectious diseases pharmacists. Pharmacotherapy., 34, 845, 2014.Search in Google Scholar

35. Ruxer J. et al.: Fosfomycin, co-trimoxazole and nitrofurantoin in the treatment of recurrent uncomplicated urinary tract infections in type 2 diabetes mellitus. Wiad. Lek., 60, 235, 2007.Search in Google Scholar

36. Sultan A. et al.: Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer? Urol. Ann., 7, 26, 2015.10.4103/0974-7796.148585431011225657539Search in Google Scholar

37. Trubiano J.A. et al.: The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br. J. Clin. Pharmacol., 79, 195, 2015.10.1111/bcp.12310430962624341410Search in Google Scholar

38. Wang A. et al.: Urinary tract infections. Prim. Care., 40, 687, 2013. 10.1016/j.pop.2013.06.00523958364Search in Google Scholar